Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
QuintilesIMS
Johnson and Johnson
Dow
Citi
Express Scripts
Medtronic
Boehringer Ingelheim
Cantor Fitzgerald

Generated: December 10, 2018

DrugPatentWatch Database Preview

Litigation Details for In Re: Rivastigmine Patent Litigation (S.D.N.Y. 2005)

« Back to Dashboard

In Re: Rivastigmine Patent Litigation (S.D.N.Y. 2005)

Docket ➤ Sign Up Date Filed 2005-02-18
Court District Court, S.D. New York Date Terminated 2008-09-25
Cause 35:271 Patent Infringement Assigned To Harold Baer Jr.
Jury Demand Defendant Referred To Magistrate Judge James C. Fran
Parties DR. REDDY'S LABORATORIES, INC.; DR. REDDY'S LABORATORIES, LTD.; NOVARTIS AG; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.; NOVARTIS PHARMA AG; NOVARTIS PHARMACEUTICALS CORPORATION; PROTERRA AG; RANBAXY INC.; RANBAXY LABORATORIES LTD.; RANBAXY PHARMACEUTICALS INC.; RIVASTIGMINE PATENT LITIGATION; SUN PHARMACEUTICAL INDUSTRIES LTD.; WATSON LABORATORIES INC.; WATSON PHARMACEUTICALS INC.
Patents 4,948,807; 5,602,176
Attorneys Barry S. White; Filko Prugo; Haejin Sarah Park; Ivan Michael. Poullaos; James Francis Hurst; James Kevin Stronski; Kimberly McGraw; Kristen G. Cowan; Leonard J. Santisi; Maurice Newmark Ross
Firms Budd Larner P.C.; Frommer Lawrence & Haug; Frommer, Lawrence & Haug, L.L.P.; Winston & Strawn; Winston & Strawn LLP (IL)
Link to Docket External link to docket
Small Molecule Drugs cited in In Re: Rivastigmine Patent Litigation
The small molecule drug covered by the patents cited in this case is ➤ Sign Up .

Details for In Re: Rivastigmine Patent Litigation (S.D.N.Y. 2005)

Date Filed Document No. Description Snippet Link To Document
2007-02-28 110 Action Against Sun for Infringement of US Patent No 5,602,176. Document filed by Novartis AG, Novartis … Document In Re: Rivastigmine Patent Litigation 18 February 2005 25… 25 September 2008 1:05-md-01661-HB-JCF Patent Defendant District Court, S.D External link to document
2007-03-19 117 Exhibit 1 and 2 Action Against Sun for Infringement of US Patent No 5,602,176., (109 in 1:05-md-01661-HB-JCF, 22 in 1:05…Claim Agaisnt Watson for Infringement of US Patent No. 5,602,176 and Dismiss without Prejudice Watson's Counterclaims… Counterclaims Concerning that Patent.. Document filed by Novartis AG, Novartis Pharma AG, Novartis International…Attachment In Re: Rivastigmine Patent Litigation 18 February 2005 25… 25 September 2008 1:05-md-01661-HB-JCF Patent Defendant District Court, S.D External link to document
2007-04-19 125 regard to the other patent, U.S. Patent No. 4,948,807 (the “‘807 patent”), remain. …of the two rivastigmine patents, U.S. Patent No. 5,602,176 (“the ‘176 patent”), and to dismiss without…on the patent because, among other things, “there is [] no guarantee that the reissue patent will eventually… : 05 MD 1661 (HB) (JCF) In Re RIVASTIGMINE PATENT : LITIGATION (MDL No. 1661), :…Pharmaceutical Ltd. (“Sun”) for infringement of U.S. Patent No. 5,602,176. The defendants External link to document
2007-06-04 127 with regard to the other patent, U.S. Patent No. 4,948,807 (the “‘807 patent”), are still at issue in …the two rivastigmine patents at issue, U.S. Patent No. 5,602,176 (“the ‘176 patent”),4 and to dismiss …regarding that patent. It also executed covenants not to sue Sun and Watson over the ‘176 patent. …concerning Novartis’ claims on both the ‘176 patent and the ‘807 patent. Among the added claims is a request…concerning the ‘807 patent. It does oppose the amendments concerning the ‘176 patent “to the extent that External link to document
2007-09-19 134 Support of Their Proposed Construction of U.S. Patent 4,948,807. Document filed by Novartis Pharma AG, Novartis… Document In Re: Rivastigmine Patent Litigation 18 February 2005 25… 25 September 2008 1:05-md-01661-HB-JCF Patent Defendant District Court, S.D External link to document
Date Filed Document No. Description Snippet Link To Document

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Harvard Business School
Fish and Richardson
McKinsey
Argus Health
Dow
QuintilesIMS
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.